Recent advances in the identification of a 1- and a 2-adrenoceptor subtypes: therapeutic implications

Bibliography

• COTECCHIA S, SCHWINN DA, RANDALL RR eta].: Molecu-lar cloning and expression of the cDNA for the hamster at-adrenergic receptor. Proc. Natl. Acad. Sci. USA (1988) 85:7159–7163.
   Google Scholar
• SCHWINN DA, LOMASNEY JW, LORENZ W eta].: Molecularcloning and expression of the cDNA for a novel cu-ad-renergic receptor subtype. J. Biol. Chem. (1990) 265:8183–8189.
   Google Scholar
• HIEBLE JP, BYLUND DB, CLARKE DE eta].: International Union of Pharmacology Recommendation for nomen-clature of aradrenoceptors: consensus update. Phar-macol Rev. (1995) 47:267–270.
   Google Scholar
• PEREZ DM, PIASCIK KMT, GRAHAM RM: Solution-phase library screening for the identification of rare clones: isolation of an al u-adr energic receptor cDNA. Mol. Phar-macol (1991) 40:876–883.
   PubMed Web of Science ®Google Scholar
• LOMASNEY JW, COTECCHIA S, LORENZ W eta].: Molecular cloning and expression of the cDNA for the au-adren-ergic receptor: the gene for which is located on human chromosome 5. J. Biol. Chem. (1991) 266:6365–6369.
   Google Scholar
• MORROW AL, CREESE I: Characterisation of at-adrener-Vic receptor subtIpes in rat brain: a re-evaluation of H-WB 4101 and H-prazosin binding. Mol. Pharmacol (1986) 29:321–330.
   PubMedGoogle Scholar
• HAN C, ABEL PW, MINNEMAN KP: ai-Adrenoceptor sub-types linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle. Nature (1987) 329:333–335.
   PubMed Web of Science ®Google Scholar
• HANFT G, GROSS G: Subclassification of ai-adrenocep-tor recognition sites by urapidil derivatives and other selective antagonists. Br. J. Pharmacol (1989) 97:691–700.
   PubMed Web of Science ®Google Scholar
• SAUSSY DL, GOETZ AS, KING HK, TRUE TA: BMY 7378 isa selective antagonist of am-adrenoceptors: further evidence that vascular at-adrenoceptors are of the am-subtype. Can. J. Physiol. Pharmacol (1994) 72\(Suppl. 0:323.
   Google Scholar
• GOETZ AS, KING HK, WARD SD et al: BMY 7378 is a selective antagonist of the D subtype of ai-adrenocep-tors. Eur.J. Pharmacol (1995) 272:R5–R6.
   PubMed Web of Science ®Google Scholar
• MURAMATSU I, OHMURA T, KIGOSHI S, HASHIMOTO S, OSHITA M: Pharmacological subclassification of ai-ad-renoceptors in vascular smooth muscle. Br. J. Pharma-col. (1990) 99:197–201.
   PubMed Web of Science ®Google Scholar
• MURAMATSU I, OHMURA T, HASHIMOTO S, OSHITA M: Functional subclassification of vascular ai-adrenocep-tors. Pharmacol Commun. (1995) 6:23–28.
   Google Scholar
• MURAMATSU I, OSHITA M, OHMURA T et al.: Pharma-cological characterisation of ai-adrenoceptor subtypes in the human prostate: functional and binding studies. Br. J. Urol. (1994) 74:572–578.
   PubMedGoogle Scholar
• FORD APDW, ARREDONDO NF, BLUE DR et al: Do aia(aft) adrenoceptors mediate prostatic smooth muscle contraction in man? Studies with a novel selective ocia adrenoceptor antagonist. Br. J. Pharmacol (1995) 114:24P.
   Web of Science ®Google Scholar
• FORD APDW, ARREDONDO NF, BLUE DR eta].: RS 17053, a selective aia-adrenoceptor antagonist, displays low affinity for functional al-adrenoceptors in prostate of man: implications for adrenoceptor classification. Mol Pharmacol (1996) 49:209–215.
   Google Scholar
• FORD APDW, DANIELS DV, CHANG DJ et al.: The putative an receptor: a distinct pharmacological state of the aia-adrenoceptor? Br. J. Pharmacol (1996b) 118:29P.
   Google Scholar
• WILLIAMS TJ, CLARKE DE, FORD APDW: Whole cell radi-oligand binding assay reveals alL adrenoceptor antago-nist profile for the human cloned aia adrenoceptor in Chinese Hamster Ovary cells. Br. J. Pharmacol (1997) (In Press.)
   Google Scholar
• KOBILKA BK, FRIELLE T, COLLINS S etal.: An intronless gene encodes a potential member of a family of recep-tors coupled to guanine nucleotide regulatory protein. Nature (1987) 329:75–79.
   Google Scholar
• REGAN JW, KOBILKA TS, YANG-FENG TL eta].:: Cloning and expression of a human kidney cDNA for an a2-ad-renergic receptor subtype. Proc. Natl. Acad. Sci. USA (1988) 85:6301–6305.
   Google Scholar
• WEINSHANK RL, ZGOMBICK JM, MACCHI M et aL: Cloning, expression and pharmacological characterisation of a human an-adrenergic receptor. Mol. Pharmacol (1990) 38:681–688.
   PubMed Web of Science ®Google Scholar
• SCHWINN DA, JOHNSON GI, PAGE SO eta].: Cloning and pharmacologic characterisation of human al-adrener-gic receptors: sequence corrections and direct compari-sons with other species homologues. j Pharmacol. Exp. Ther. (1995) 272:134–142.
   Google Scholar
• HIEBLE JP, RUFFOLO RR: Subclassification and nomen-clature of al- and a2-adrenoceptors. Prog. Drug Res (1996) 47:81–130.
   PubMedGoogle Scholar
• GUYER CA, HORSTMAN DA, WILSON AL eta].: Cloning, sequencing and expression of the gene encoding the porcine a2-adrenergic receptor. J. Biol. Chem. (1990) 265:17307–17317.
   Google Scholar
• HARRISON JK, D'ANGELO DD, ZENG D, LYNCH KR: Phar-macological characterisation of rat a2-adrenergic re-ceptors. Mol Pharmacol (1991) 40:407–412.
   PubMedGoogle Scholar
• LANIER SM, DOWNING S, DUZIC E, HOMCY CJ: Isolation of rat genomic clones encoding subtypes of the a2-ad-renergic receptor. J. Biol. Chem. (1991) 266:10470–10478.
   PubMed Web of Science ®Google Scholar
• LINK R, DAUNT D, BARSH G, CHRUSCINSKI A, KOBILKA B: Cloning of two mouse genes encoding a2-adrenergic receptor subtypes and identification of a single amino acid in the mouse a2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol. Phar-macol. (1992) 42:16–27.
   PubMed Web of Science ®Google Scholar
• SVENSSON SPS, BAILEY TJ, PORTER AC, RICHMAN JG, REGAN JW: Heterologous expression of the cloned guinea-pig a2a, an and a2c adrenoceptor subtypes. Biochem. Pharmacol (1996) 51:291–300.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, RUFFOLO RR: The use of a-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol. Res. (1996) 33:145–160.
   PubMed Web of Science ®Google Scholar
• TRENDELENBURG AU, WAHL CA, STARKE K: Antagonists that differentiate between a2A and am adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. (1996) 353:24–29.
   Google Scholar
• BYLUND DB, REGAN JW, FABER JE et al.: Vascular a-ad-renoce ptors: from the gene to the human. Can. J. Physiol. Pharmacol (1995) 73:533–553.
   PubMedGoogle Scholar
• MURPHY TJ, BYLUND DB: Characterisation of alpha-2 adrenergic receptors in the OK cell, an opossum kidney cell line. J. Pharmacol Exp. Ther. (1988) 244:571–578.
   PubMed Web of Science ®Google Scholar
• BYLUND DB, RAY-PRENGER C: Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. J. Pharmacol. Exp. Ther. (1989) 251:640–644.
   PubMed Web of Science ®Google Scholar
• TRENDELENBURG AU, LIMBERGER N, RUMP LC: a2-adren-ergic receptors of the a2c subtype mediate inhibition of norepinephrine release in human kidney cortex. Mol Pharmacol (1994) 45:1168–1176.
   PubMed Web of Science ®Google Scholar
• RAZ S, ZEIGLER M, CAINE M: Pharmacological receptors in the prostate. Br. J. Urol. (1973) 45:663–667.
   Google Scholar
• CAINE M, RAZ S, ZIEGLER M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck Br. J. Urol. (1975) 47:193.
   Web of Science ®Google Scholar
• HEDLUND H, ANDERSON K, LARSSON B: Alpha-adreno-ceptors and muscarinic receptors in the is olated human prostate. J. Urol. (1985) 134:1291–1297.
   PubMed Web of Science ®Google Scholar
• JAMES S, CHAPPLE CR, FHILLIPS MI et al.: Autoradiog-raphic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human pros-tate. J. Urol (1989) 142:438–444.
   PubMed Web of Science ®Google Scholar
• YAMADA S, SUZUKI M, KATO Y et al: Binding charac-teristics of naftopidil and ai-adrenoceptor antagonists to prostatic a-adrenoceptors in benign prostatic hyper-trophy. Life Sci. (1991) 50:127–135.
   Web of Science ®Google Scholar
• HIEBLE JP, CAINE M, ZALAZNIK E: In vitro charac-terisation of the a-adrenoceptors in human prostate. Eur. I Pharmacol. (1985) 107:111–117.
   PubMed Web of Science ®Google Scholar
• GUH JH, CHUEH SC KO FN, TENG CM: Characterisation of ai-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. Br. Pharmacol. (1995) 115:142–146.
   PubMed Web of Science ®Google Scholar
• CAINE M: Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol. Clin. North Am. (1990) 17:641–649.
   PubMed Web of Science ®Google Scholar
• DESGRANDCHAMPS F, TEILLAC P: The role of growth factors in the pathogenesis of benign prostatic hyper-plasia. Biomed. Pharmacother. (1994) 48 (Suppl. 1):19s–23s.
   Google Scholar
• HU ZW, SHI XY, HOFFMAN BB: Insulin and insulin-like growth factor differentially induce alpha 1 adrenergic receptor subtype expression in rat vascular smooth muscle cells../. Gin. Invest. (1996) 98:1826–1834.
   PubMed Web of Science ®Google Scholar
• HU ZW, SHI XY, UN RZ, HOFFMAN BB: Alpha-1 adrener-gic receptor subtypes activate p70 and p90 isoforms of S6 ribosomal kinases via Ras independent and depend-ent pathways. International Symposium on Prostate Growth. Washington, DC (1996). Abstract 62.
   Google Scholar
• ALLEN LF, FERGUSON SB, MOORE ME: Doxazosin inhibi-tion of prostate cancer cell growth. International Sympo-sium on Prostate Growth. Washington, DC (1996). Abstract
   Google Scholar
• HATANO A, TANG R, WALDEN PD, LEPOR H: The alpha-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate. Eur. J. Pharmacol. (1996) 313:135–143.
   PubMed Web of Science ®Google Scholar
• YANG G, TIMME TL, PARK SH et al: A mouse model for human BPH and its use to test the effects of doxazosin in vivo. International Symposium on Prostate Growth. Wash-ington, DC (1996) Abstract 26.
   Google Scholar
• SYNAPTIC; GLUCHOWSKI C, WETZEL JM, CHIU G et al.: Dihydropyridines and new uses thereof. WO 94/22829 (October 13, 1994).
   Google Scholar
• SYNAPTIC; GLUCHOWSKI C, FORRAY C, CHIU G et al: Use of aft specific compounds to treat benign prostatic hyperplasia. U55403847 (April 4, 1995).
   Google Scholar
• KENNY B, MILLER A, 0' CONNELL J, NAYLOR A: The in vitro pharmacological selectivity profile of several at-adrenoceptor antagonists at cloned and p rostatic al -ad-renoceptors. Xllth Congress of the European Association of Urology Paris (1996). Abstract 29.
   Google Scholar
• LEONARDI A, TESTA R, MOTTA G et al: at-Adrenoceptors: subtype and organ selectivity of different agents. In: Perspective in Receptor Research. Giardina D, Piergentili A, Pigini M (Eds.), Elsevier (1996):135–152.
   Google Scholar
• TESTA R, GUARNERI L, ANGELICO P et al: Pharmacologi-cal characterisation of the uroselective at-antagonist Rec 15/2739 (SB 216469): role of the an-adrenoceptor in tissue selectivity. Part 11.1 Pharmacol. Exp. Ther. (1997) (In Press.)
   Google Scholar
• BLUE DR, FORD APDW, MORGANS DJ, PADILLA F, CLARKE DE: Preclinical pharmacology of a novel ata/ait-ad-renoceptor antagonist, RS 100975. Neurourol. Urodyn. (1996) 15:346.
   Google Scholar
• DREWRY DH: Alpha lA antagonists for benign prostatic hyperplasia. 212th National ACS Meeting (1996). Abstract 206.
   Google Scholar
• TESTA R, TADDEI C, POGGESI E et al: Rec 15/2739 (SB 216469), a novel prostate selective at-adrenoceptor antagonist. Pharmacol Commun. (1995) 6:79–86.
   Google Scholar
• KENNY BA, MILLER AM, WILLIAMSON IJR et al: Evaluation of the pharmacological selectivity profile of at-adreno-ceptor antagonists at prostatic apadrenoceptors: bind-ing, functional and in vivo studies. Br. J. Pharmacol (1996) 118:871–878.
   PubMed Web of Science ®Google Scholar
• GEORGE P, BORG F, O'CONNOR S et al: Uroselectiveat-adrenoceptor antagonists for the treatment of be- nign prostatic hypertrophy. Eur. J. Med. Chem. (1995) 30 (Suppl.):299s–310s.
   Google Scholar
• MARSHALL I, BURT RP, GREEM M, HUSSAIN MB, CHAPPLE CR: Different subtypes of aia adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br. J. Pharmacol (1996) 119:407–415.
   PubMed Web of Science ®Google Scholar
• MARSHALL I, BURT RP, GREEN M et al: RS 17053 distin-guished between a ta-adrenoceptors in human prostate and the ata subtype clone. Neurourol Urodyn. (1996) 15:343–344.
   Google Scholar
• TESTA R, POGGESI E, TADDEI C et al: Rec 15/2739, a newat-antagonist selective for the lower urinary tract: in vitro studies. Neurol Urodyn. (1994) 13:473–474.
   Google Scholar
• TESTA R, SIRONI G, COLOMBO D, GRETO D, LEONARDIA: Rec 15/2739, a new al-antagonist selective for the lower urinary tract: in vivostudies.Neurot Urodyn. (1994) 13:471–473.
   Google Scholar
• LEONARDI A, HIEBLE JP, GUARNERI L et al.: Pharma-cological characterisation of the uroselective al-antago-nist Rec 15/2739 (SB 216469): role of the an adrenoceptor in tissue selectivity. Part L j Pharmacol Exp. Ther. (1997) (In Press.)
   Google Scholar
• BLUE D, ZHU OM, ISOM P etal.: Effect of al-adrenoceptor antagonists in dog prostate/blood pressure models. FASEB J (1996) 10:A425.
   Google Scholar
• KATWALA SP, MILICIC IP, HANCOCK AA, FERWIN JF, BRUNE ME: Differential effects of various alpha-1 ad-renoceptor antagonists on urogenital and vascular smooth muscle in vivo. FASEB J (1996) 10:A425.
   Google Scholar
• VERFUTH F, ERDBRUGGER W, MICHEL MC: Comparison of Rec 15/2739 and terazosin apadrenoceptor subtype affinities. Br. J. Pharmacol. (1995) 116:290P.
   Google Scholar
• CHESS-WILLIAMS R, CHAPPLE CR et al.: The effects of SB216469, an antagonist which discriminates between the alpha (1A) adrenoceptor and the human prostatic alpha (1) adrenoceptor. Br. J. Pharmacol. (1996) 119:1093–1100.
   PubMed Web of Science ®Google Scholar
• TESTA R, GUARNERI L, TADDAI C et al: Functional an-tagonistic activity of Rec 15/2739, a novel alpha-1 an-tagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J. Pharmacol. Exp. Ther. (1996) 277:1237–1246.
   PubMed Web of Science ®Google Scholar
• ERI LM, TVETER KJ: a-Blockade in the treatment ofsymptomatic benign prostatic hyperplasia. J. Urol (1995) 154:923–934.
   PubMed Web of Science ®Google Scholar
• MARTIN D, JAMMES D, ANGEL I: Effects of alfuzosin on urethral and blood pressures in conscious male rats. Life Sci. (1995) 57:387–391.
   PubMedGoogle Scholar
• FORRAY C, BARD JA, WETZEL JM et al.: The al-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human ate subtype. Mol Pharmacol (1994) 45:703–708.
   PubMed Web of Science ®Google Scholar
• SCOTT MA, ABRAMS PH: Indoramin in benign prostatichypertrophy: a placebo-controlled trial. Br. J. Urol (1991) 67:499–501.
   PubMedGoogle Scholar
• IACOVOU JW, DUNN M: Indoramin: an effective newdrug in the management of bladder outlet obstruction. Br. J. Urol (1987) 60:526–532.
   PubMedGoogle Scholar
• CHOW W, HAHN D, SANDHU D: Multicentre controlled trial of indoramin in the symptomatic relief of benign prostatic hypertrophy. Br. J. Urol (1990) 65:36–38.
   PubMedGoogle Scholar
• SHIBATA K, FOGLAR R, HORIE K etal: KMD-3213, a novel, potent aia adrenoceptor selective antagpnist. Charac-terisation using recombinant human ai-adrenoceptors and native tissue. Mol. Pharmacol (1995) 48:250–258.
   Google Scholar
• TAGUCHI K, SAITOH M, SATO S, ASANO M, MICHEL MC: Effects of tamsulosin metabolites at alpha-1 adrenocep-tor subtypes. J. Pharmacol Exp. Ther. (1997) 280:1–5.
   PubMed Web of Science ®Google Scholar
• YAMADA S, SUZUKI M, TANAKA C et al: Comparative study on ai-adrenoceptor antagonist binding in human prostate and aorta. Clin. Exp. Pharmacol Physic)]. (1994) 21:405–411.
   PubMed Web of Science ®Google Scholar
• YAMADA S, TANAKA C, KIMURA R, KAWABE K: Alphai-adrenoceptors in human prostate: characterisation and binding characteristics of alphat-antagonists. Life Sci. (1994) 54:1845–1854.
   PubMed Web of Science ®Google Scholar
• HARADA K, OHMORI M, FUJIMURA A: Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular ai-adrenoceptors in humans. Naunyn-Schmiodeberg's Arch. Pharmacol (1996) 354:557–561.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, KITADE S, OSADA Y: Comparative study of alpha-1 blacker in the proximal urethral function using an in vivo model of isovolumetric pressure gen-eration. Proceedings of the 23rd Congress of the International Society of Urology. Sydney, Australia (1994). Abstract 672.
   Google Scholar
• SUDOH K, INAGAKI 0, ASANO M: The effect of YM12617-1, a selective alphal-adrenoceptor antagonist, on mic-turition reflexes and urethral pressure in anesthetized dogs and rats. fpn. Pharmacol. (1990) 52 (Suppl. 1):131P.
   Google Scholar
• KENNY BA, NAYLOR AM, CARTER AJ et al.: Effect of ai-adrenoceptor antagpnists at prostatic pressure and blood pressure in the anesthetised dog. Urology (1994) 44:52–57.
   PubMed Web of Science ®Google Scholar
• BRUNE ME, KATWALA SP, MILICIC I, HANCOCK AA, KER-WIN JF: Simultaneous evaluation of the effects of ai-ad-renergic antagonists on vascular and prostatic smooth muscle in intact conscious dogs. J. Urol (1996) 155 (Suppl.):332A.
   Google Scholar
• WILDE MI, MCTAVISH D: Tamsulosin. Drugs (1996) 52:883–898.
   PubMed Web of Science ®Google Scholar
• KAWABE K: Effect and safety of tamsulosin, the prostate specific ai-blocker, in the treatment of BPH. Akt. Urol. (1996) 27(Suppl.):25–26.
   Google Scholar
• OKADA H, KAWAIDA N, OGAWA T et al.: Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. Scand.J. Urol. Nephrol. (1996) 30:379–385.
   PubMed Web of Science ®Google Scholar
• TSUNO0 M, SHISHITO A, SOEISHI Y: Phase I clinical trial of YM617, a new at-adrenoceptor antagonist - first report: a single oral dose of conventional formulation in healthy male subjects. Rinsho Iyaku (1990) 6:2503–2528.
   Google Scholar
• LEPOR H: Clinical evaluation of tamsulosin, a prostate selective alpha 1C antagonist. J. Urol. (1995) 153(Suppl.): 274A.
   Google Scholar
• ANDERSSON KE: Prostatic and extraprostatic a-adreno-captors. Contributions to the lower urinary tract symp-toms in benign prostatic hyperplasia. Scand J. Urol. Nephrol. (1996) 457:105–111.
   Google Scholar
• ISHIZUKA 0, PERSSON K, MATTIASSON A et al.: Micturi-tion in conscious rats with and without bladder outlet obstruction: role of spinal ai-adrenoceptors. Br. J. Phar-macol. (1996) 117:962–966.
   Google Scholar
• RAMAGE AG, WYLLIE MG: A comparison of the effects of doxazosin and terazosin on the spontaneous sympa-thetic drive to the bladder and related organs in anes-thetized cats. Eur.j Pharmacol (1995) 294:645–650.
   PubMed Web of Science ®Google Scholar
• TESTA R, HIEBLE JP, GUARNERI L eta].: The potency of ai-adrenoceptor antagonists for lower urinary tract tissues is related to their affinity for the all-adrenocep-tor subtype. Neurourol. Urodyn. (1996) 15:346–347.
   Google Scholar
• HIEBLE JP, SULPIZIO AC, NASELSKY DP, TESTA R, LEONARDI A: Interaction of Rec 15/2730 (SB 216469) with oci-adrenoceptor subtypes in vascular and urogeni-tal tissues. 26th Annual Meeting of the International Conti-nence Soci0). Barbalias GA (Ed.), Monduzzi, Bologna (1996) :101–105.
   Google Scholar
• ABBOTTS LABS.; MEYER MD, CARROLL WA, DRIZIN I et aL:Bicyclic substituted hexahydrobenze[e] isoindole al-pha-1 adrenergic antagonists. WO 96/22991 (August 1, 1996).
   Google Scholar
• ABBOTTS LABS.; MEYER MD, ALTENBACH RJ, BASHA FZet al.: Tricyclic substituted hexahydrobenze[e]isoindole alpha-1 adrenergic antagonists. WO 96/22992 (August 1, 1996).
   Google Scholar
• MURAMATSU I, TAKITA H, SUZUKI F et al: Subtype selectivity of a new aradrenoceptor antagonist, JTH-601: comparison with prazosin. Eur. J. Pharmacol (1996) 300:155–157.
   PubMed Web of Science ®Google Scholar
• KENNY BA, CHALMERS DH, PHILPOTT PC, NAYLOR AM:Characterisation of an am adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br. Pharmacol. (1995) 115:981–986.
   PubMed Web of Science ®Google Scholar
• DENG XF, CHEMTOB S, VARMA DR: Characterisation ofaiD adre nocept or subtype in rat myocardium, aorta and other tissues. Br. J. Pharmacol. (1996) 119:269–276.
   PubMed Web of Science ®Google Scholar
• YAMAGISHI R, AKIYAMA K, NAKAMURA S eta].: Effect of KMD-3213, an ala adrenoceptor selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur.j Pharmacol. (1996) 315:73–79.
   Google Scholar
• VAN DER GRAAF PH, SHANKLEY NP, BLACK JW: Analysis of the activity of ai-adrenoceptor antagonists in rat aorta. Br. J. Pharmacol. (1996) 118:299–310.
   PubMed Web of Science ®Google Scholar
• AUGUET M, DELEFLOTTE S, CHABRIER PE: Different ai-adrenoceptor subtypes mediate contraction in rabbit aorta and urethra. Eur. J. Pharmacol. (1995) 287:153–161.
   PubMed Web of Science ®Google Scholar
• LEECH CJ, FABER JE: Different a-adrenoceptor subtypes mediate constriction of arterioles and venules. Am. J. Physiol. (1996) 270:H710–H722.
   PubMed Web of Science ®Google Scholar
• IPSEN M, DRAGSTED N, MULVANY MJ: Functional distri-bution of alpha-1 adrenoceptor subtypes in mesenteric small arteries of the rat. Pharmacol. Res (1995) 31 (Suppl.) :192.
   Google Scholar
• ZHOU L, VARGAS HM: Vascular am adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat. Eur.j Pharmacol (1996) 305:173–176.
   PubMed Web of Science ®Google Scholar
• GUILMARD C, AUGUET M, CHABRIER PE: Pharmacologi-cal characterisation of alphat-adrenoceptor subtype mediating regulation of arterial pressure and urethral perfusion pressure in the anesthetized rat J. Auton. Pharmacol (1996) 16:197–203.
   PubMedGoogle Scholar
• DELAFLOTTES, AUGUET M, CHABRIER PE: Pharmacologi-cal evidence that different alpha-1 adrenoceptor sub-types mediate contraction in rabbit prostate and hypogastric artery. Acta Physiol. Scand (1996) 158:241–251.
   PubMedGoogle Scholar
• PIASCIK MT, SMITH MS, SOLTIS EE, PEREZ DM: Identifica-tion of the mRNA for the novel am-adrenoceptor and two other ai-adrenoceptors in vascular smooth muscle. Mot. Pharmacol. (1994) 46:30–40.
   PubMed Web of Science ®Google Scholar
• SCHWINN DA, PAGE SO, MIDDLETON JP et al.: The ocic-adr ene rgic receptor: characterisation of signal transduction pathways and mammalian tissue hetero-geneity. Mol. Pharmacol. (1991) 40:619–626.
   PubMed Web of Science ®Google Scholar
• PRICE DT, LEFKOWITZ RJ, CARON MG, BERKOWITZ D, SCHWINN DA: Localization of mRNA for three distinct ai-adrenergic receptor subtypes in human tissues: im-plications for human a-adrenergic physiology. Mol. Pharmacol (1994) 45:171–175.
   PubMed Web of Science ®Google Scholar
• DIEHL NL, SHREEVE SM: Identification of the atc adreno-ceptor in rabbit arteries and the human saphemus vein using the polymerase chain reaction. Eur. j Pharmacol (1994) 268:393–398.
   PubMed Web of Science ®Google Scholar
• LAZ TM, FORRAY C, SMITH KE et al: The rat homologue of bovine atc-adrenergic receptor shows the pharma-cological properties of the classical am subtype. Mol. Pharmacol. (1994) 46:414–422.
   PubMed Web of Science ®Google Scholar
• WILLIAMS TJ, CLARKE DE: Characterisation of at-adreno-ceptors mediating vasoconstriction to noradrenaline and nerve stimulation in the isolated per fused mesen-tery of rat. Br. J. Pharmacol. (1995) 114:531–536.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, RUFFOLO RR, Jr., SULPIZIO AC etal.: Functional subclassification of a2-adrenoceptors. Pharmacol Com-mun. (1995) 6:91–97.
   Google Scholar
• SMITH MS, SOLTIS EE, PIASCIK MT: Chloroethylclonidine sensitive alp hal-adrenoceptor subtypes and the regu-lation of renal blood flow in the conscious rat Pharma-col. Comm 1.117. (1992) 2:195–202.
   Google Scholar
• PIASCIK MT, SPARKS MS, PRUITT TA: Effect of chlo-roethylclonidine on arterial blood pressure and heart rate in the conscious rat. J. Pharmacol. Exp. Ther. (1992) 262:901–906.
   PubMed Web of Science ®Google Scholar
• VARGAS HM, CUNNINGHAM D, ZHOU L, HARTMAN HB, GORMAN AJ: Cardiovascular effects of chloroethylclo-nidine, an irreversible at-adrenoceptor antagonist, in the anesthetized rat. A pharmacological analysis in vivo and in vitro. J. Pharmacol Exp. Ther. (1993) 267:264–272.
   Google Scholar
• VARGAS HM, ZHOU L, GORMAN AJ: Role of vascular alpha-1 adrenoceptor subtypes inthe pressor response to sympathetic nerve stimulation in the pithed rat. J. Pharmacol. Exp. Ther. (1994) 271:748–754.
   PubMed Web of Science ®Google Scholar
• GIARDINA D, CRUCIANELLI M, MELCHIORRE C, TADDEI C, TESTA R: Receptor binding profile of cyclazosin, a new a1B-adrenoceptor antagonist Eur. J. Pharmacol. (1995) 287:13–16.
   Google Scholar
• HIEBLE JP: Structure-activity relationships for activation and blockade of B-adrenoceptors. In: P-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology. Ruffolo RR, Jr. (Ed.), Basel, Karger. Prog. Basic Clin. Pharmacol (1991) 7:105–172.
   Google Scholar
• NICHOLS AJ, SULPIZIO AC, ASHTON DJ, HIEBLE JP, RUF-FOLO RR, Jr.: The interaction of the enantiomers of carve dilol with at- and 131-adrenoceptors. ChiraW (1989) 1:265–270.
   Google Scholar
• BRIL A, FEUERSTEIN GZ, RUFFOLO RR, Jr.: Carvedilol: a new paradigm for the treatment of congestive heart failure. Exp. Opin. Invest Drugs (1996) 5:1523–1529.
   Google Scholar
• MACMILLAN LB, HEIN L, SMITH MS, PIASCIK MT, LIMBIRD LE: Central hypotensive effects of the aza-adrenergic receptor subtype. Science (1996) 273:801–803.
   PubMed Web of Science ®Google Scholar
• LINK RE, STEVENS MS, KULATUNGA M et al.: Targeted inactivation of the gene encoding the mouse a2c adreno-ceptor homolog. Mol. Pharmacol (1995) 48:48–55.
   PubMed Web of Science ®Google Scholar
• LINK RE, DESAI K, HEIN L etal: Cardiovascular regulation in mice lacking a2-adrenergic receptor subtypes b and c. Science (1996) 273:803–805.
   PubMed Web of Science ®Google Scholar
• ERNSBERGER PR, WESTBROOKS KL, CHRISTEN MO, SCHAFER SG: A second generation of centrally acting antihypertensive agents act on putative Ii-imidazoline receptors. J. Cardiovasc. Pharmacol (1992) 20 (Suppl. 4):S1–S10.
   Google Scholar
• HIEBLE JP, KOLPAK DC: Mediation of the hypotensive action of systemic clonidine in the rat by a2-adre nocep-tors. Br. J. Pharmacol (1993) 110:1635–1639.
   PubMed Web of Science ®Google Scholar
• SZABO B, URBAN R, STARKE K: Sympathoinhibition by rilmenidine in conscious rabbits: involvement of a2-ad-renoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol (1993) 348:593–600.
   Google Scholar
• PATEL SS, DUNN CJ, BRYSON HM: Epidural clonidine - a review of its pharmacology and efficacy in the manage-ment of pain during labour and postoperative and intractable pain. CNS Drugs (1996) 6:474–479.
   Web of Science ®Google Scholar
• MJAHED K, ELHARRAR N, HAMDANI M, AMRAOUI M, BENAGUIDA M: Lidocaine-clonidine retrobulbar block for cataract surgery in the elderly. Regional Anesthes. (1996) 21:569–575.
   PubMed Web of Science ®Google Scholar
• MAX MB, SCHAFER SC, CULNANE M, DUBNER R, GRACELY RH: Association of pain relief with drug side-effects in post herpe tic neuralgia: a single dose study of clonidine, codeine, ibuprofen and placebo. Clin. Pharmacol Ther. (1988) 43:363–371.
   PubMed Web of Science ®Google Scholar
• BERRY H, HUTCHINSON DR: A multicentre placebo-con-trolled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J. Int. Med. Res. (1988) 16:75–82.
   PubMed Web of Science ®Google Scholar
• BERRY H, HUTCHINSON DR: Tizanidine and ibuprofen in acute low-back pain: results of a double-blind mul-ticentre study in general practice. J. Int. Med. Res. (1988) 16:83–91.
   PubMed Web of Science ®Google Scholar
• VICKERY RG, SHERIDAN BC, SEGAL IS, MAZE M: Anaes-thetic and hemodynamic effects of the stereoisomers of medetomidine, an a2-adrenergic agonist, in ha-lot hane-anesthetized dogs. Anesthes. Analg. (1988) 67:611–615.
   PubMed Web of Science ®Google Scholar
• SCHEININ M, KALLIO A, KOULU M, VIIKARI J, SCHEININ H: Sedative and cardiovascular effects of medetomidine, a novel selective cc2-adrenoceptor agonist, in healthy volunteers. Br. J. Clin. Pharmacol (1987) 24:443–451.
   PubMed Web of Science ®Google Scholar
• DOZE VA, CHEN B, MAZE M: Dexmedetomidine pro-duces a hypnotic-anaesthetic action in rats via activa-tion of central alpha-2 adrenoceptors. Anesthesiology (1989) 71:75–79.
   PubMed Web of Science ®Google Scholar
• SAMSO E, VALLES J, POL 0, GALLART L, PUIG MM: Com-parative assessment of the anaesthetic and analgesic effects of intramuselar and epidural clonidine in hu-mans. Can. J. Anesthesia (1996) 43:1195–1202.
   PubMed Web of Science ®Google Scholar
• HAO JX, YU W, XU XJ, WIESENFELDHALLIN Z: Effects of intrathecal vs. systemic clonidine in treating chronic allodynia-like response in spinally injured rats. Brain Res. (1996) 736:28–34.
   Google Scholar
• AGHAJANIAN GK: The neurobiology of opiate with-drawal: receptors second messengers and ion chan-nels. Psychiat. Lek. (1985) 111:57–60.
   Google Scholar
• HUGHES PL, MORSE RM: Use of clonidine in a mixed-drug detoxification regimen: possibility of masking of clinical signs of sedative withdrawal. Mayo Clin. Proc. (1985) 60:47–49.
   PubMed Web of Science ®Google Scholar
• WASHTON AM, RESNICK RB: Outpatient opiate detoxifi-cation with clonidine. j Clin. Psychiat (1982) 43:39–41.
   PubMed Web of Science ®Google Scholar
• BEARN J, GOSSOP M, STRANG J: Randomized double-blind comparison of lofexidine and methadone in the inpatient treatment of opiate withdrawal. Drug Alcohol Dep. (1996) 43:87–91.
   PubMed Web of Science ®Google Scholar
• DEUTSCH ES, NADKAMI VM: Clonidine prophylaxis for narcotic and sedative withdrawal syndrome following laryngotracheal reconstruction. Arch. Otolmyngol. Head Neck Surg (1996) 122:1232–1238.
   Google Scholar
• HUNT RD, CAPPER L, O'CONNELL P: Clonidine in child and adolescent pscychiatry. J. Child. Adolesc. Psychophar-macol (1990) 1:87–102.
   PubMedGoogle Scholar
• HUNT RD: Treatment effects of oral and transdermal clonidine in relation to methylphenidate - an open pilot study in ADHD. Psychopharm. Bull. (1987) 23:111–114.
   PubMed Web of Science ®Google Scholar
• WILENS TE, BIEDERMAN J, SPENCER T: Clonidine for sleep disturbances associated with attention-deficit hy-peractivity disorder. J. Am. Acad. Child. Adolesc. PFchiat (1994) 33:424–426.
   PubMed Web of Science ®Google Scholar
• HUNT RD, ARNSTEN AFT, ASBELL MD: An open trial of guanfacine in the treatment of attention-deficit hyper-activity disorder. J. Am. Acad. Child. Adolesc. Psy (1995) 34:50–54.
   PubMed Web of Science ®Google Scholar
• PINDER RM: a2-Adrenoceptor antagonists as antidepres-sants. Drugs Future (1985) 10:841–857.
   Google Scholar
• CLAGHORN JL, JOHNSTON EE, STUDEBAKER SL, AJEMAN SA: The effectiveness of 6-azamianserin (Org 3770) in depressed outpatients. Psychopharmacol Bull. (1987) 23:160–161.
   PubMed Web of Science ®Google Scholar
• PINDER RM, WIERINGA JH: Third-generation antidepres-sants. Med. Res. Rev. (1993) 13:259–325.
   PubMedGoogle Scholar
• ROESLER JM, MCCAFFERTY JP, DEMARINIS RM, MAT-THEWS WD, HIEBLE JP: Characterisation of the antihy-pertensive activity of SK&F 86466, a selective a2-antagonist, in the rat. J. Phannacol Exp. Ther. (1986) 236:1–7.
   PubMed Web of Science ®Google Scholar
• RUFFOLO RR, Jr, BONDINELL WE, HIEBLE JP: a- and 3-adrenoceptors: from the gene to the clinic. 2. Struc-ture-activity relationships and therapeutic applica-tions. J. Med. Chem. (1995) 38:3415–3444.
   Google Scholar
• BROWN MJ: Investigation of alpha2-adrenoceptors in humans. Am. J. Med. (1989) 87(Suppl. 3C):6S–9S.
   Google Scholar
• WILLETTE RN, HIEBLE JP, SAUERMELCH CF: The role of alpha adrenoceptor subtypes in sympathetic control of the acral-cutaneous microcirculation. j Pharmacol Exp. Ther. (1991) 256:599–605.
   PubMed Web of Science ®Google Scholar
• FREEDMAN RR, SABHARWAL SC, MOTEN M, MIGALY P: Local temperature modulates al- and a2-adrenergie vasoconstriction in men. Am. J. Physiol (1992) 263 : H1197–H1200.
   PubMed Web of Science ®Google Scholar
• EKENVALL L, LINDBLAD LE, NORBECK 0, ETZELL BM: a-Adrenoceptors and cold-induced vasoconstriction in human finger skin. Am. j Physiol (1988) 255:H1000–H1003.
   PubMed Web of Science ®Google Scholar
• RICHFLSEN B: Increased alpha2- but similar beta-adren-ergic receptor activities in subcutaneous gluteal adipo-cytes from females compared with males. Eur. J. Clin. Invest. (1986) 16:302–309.
   PubMed Web of Science ®Google Scholar
• MAURIEGE P, GALITZKY J, BERLAN M, LAFONTAN M: Heterogeneous distribution of beta- and alpha-2 ad-renoceptor binding sites in human fat cells from vari-ous fat deposits: functional consequences. Eur. j Clin. Invest. (1987) 17:156–165.
   PubMed Web of Science ®Google Scholar
• HIEBLE JP, SOLLEVELD HA, SULPIZIO AC: Effects of an alpha2 adrenoceptor antagonist on weight gain and lipolysis in the rat. Int J. Obesity (1990) 14 (Suppl. 2):77.
   Google Scholar
• ZAHORSKAK-MARKIEWICZ B, KUCIO C, PISKORSKA D: Adrenergic control of lipolysis and metabolic re-sponses in obesity. Horm. Metabol. Res. (1986) 18:693–696.
   PubMed Web of Science ®Google Scholar
• BERLIN I, STALL-BOURDILLON A, THUILLIER Y, TURPIN G, PUECH AJ: Absence d'efficacite de la yohimbine dans le traitement de l'obesite. j Pharmacol Paris (1986) 17:343–347.
   PubMedGoogle Scholar
• ORIOWO MA, HIEBLE JP, RUFFOLO RR. Jr.: Evidence for heterogeneity of prejunctional a2-adrenoceptors. Phar-macology (1991) 43:1–13.
   Google Scholar
• DODA M: Role of different subtypes of adrenoceptors in pressor responses to catecholamines released from sympathetic nerve endings. Brain Res. Bull. (1997) 42:51–57.
   PubMed Web of Science ®Google Scholar
• LAWS-RICKER L, CUNNINGHAM DM, VARGAS HM: Cardio-vascular profile of P7480, a novel am-adrenoceptor agonist, in conscious rats. Pharmacologist (1997) 39:44.
   Google Scholar
• XIAO L, VARGAS HM, BROOKS K, JEFFRIES WB: Compari-son of affinities of novel agonists at cloned rat oci-ad-renoceptor subtypes. Pharmacologist (1997) 39:43.
   Google Scholar
• BARRAS M, VAN DER GRAAF PH, PHILLIPO C, ANGEL I: Comparison ofthe efficacy of aradrenoceptor agonists in rabbit isolated urethra and mesenteric artery. XlIth Congress of the European Association of Urology. Paris (1997).
   Google Scholar
• TANIGUCHI N, HAMADA K, OGASAWARA T et al.: NS-49, an alpha (1A) adrenoceptor agonist, selectively in-creases intraurethral pressure in dogs. Eur. I Pharmacol (1996) 318:117–122.
   PubMed Web of Science ®Google Scholar
• DODA M: Role of different subtypes of adrenoceptors in pressor responses to catecholamines released from sympathetic nerve endings. Brain Res. Bull. (1997) 42:51-57. J Paul Hieblet & Robert R Ruffolo, Jr.
   Google Scholar